多药耐药基因1 P-糖蛋白在肺癌中的表达及其临床意义

Expression and clinical significance of P-glycoprotein in lung cancer

采用 SABC免疫组化法对 10 6例肺癌组织进行多药耐药基因 1P-糖蛋白 (以下简称 P- gp)表达检测 ,并进行相关临床因素分析。10 6例标本中 ,P- gp阳性率 5 6 .6 % ,低分化鳞癌、腺癌与中、高分化型 P- gp阳性率分别为4 2 .9%及 78.6 % ,差别显著 (P<0 .0 5 ) ;P- gp阳性表达的鳞癌 (5 5 .6 % )与腺癌 (86 .7% )、小细胞未分化癌 (SCL C)(18.1% )与非小细胞未分化癌 (NSCL C) (6 6 .7% )之间均有显著性差异 (P均 <0 .0 5 ) ;TNM分期 ～ 期 P- gp阳性率分别为 5 5 .6 %、5 2 .6 %、5 6 % ,统计学无差异 (P>0 .0 5 ) ;有淋巴结转移的 P- gp阳性表达为 5 9% ,无淋巴结者为 5 7.2 % ,二者无显著差异 (P>0 .0 5 )。32例接受化疗 P- gp阳性者的有效率为 2 2 .2 % ,阴性者为 5 7.1% ,有显著性差异 (P<0 .0 5 )。认为 P- gp可作为预示化疗敏感性的分子标记物 。

To explore the expression and clinical significance of P gp in lung cancer.106 patients were selected based on the criterion that they had received no chemotherapy before radiotherapy.Immunohistochemi stry was performed using the streptavidin biotin complex method.32 patients were treated by chemotheray.After compared the poorly differentiated squamous carcinomas and adenocarcinomas with their moderate and well differentiated types,the MDR1 P gp expression was 42.9% and 78.6%,respectively(P<0.05),and there was statistic difference between them.The P gp's positive rate of adenocarcinoma was 86.7% (P<0.05).The P gp's positive rate of SCLC was 18.1%,while NSCLC was 66.7%(P<0.05),For stage Ⅰ,Ⅱ and Ⅲ tumors,the P gp's positive rates were 55.6%,52.6%,56%,there was no statistic difference among them.The P gp's positive rate of tumors with lymph node metastasis was 59%,while tumors without lymph node metastasis had the positive rate of 57.2%(P<0.05).The response rate to chemotherapy in patients with over expression of P gp was lower than that of patients without such expression(P<0.05).These suggest that P gp expression in lung cancer is related to drug ressitance and it is an useful prognostic marker.